Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107886 · ClinicalTrials.gov registry record · Phase 4
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 18,206
- Enrollment target
NCT01107886: Completed Phase 4 study, sponsored by AstraZeneca.
NCT01107886 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 18,206 participants, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (3428% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01107886, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18,206 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
Primary Outcome
Participants with CV death, non-fatal MI or non-fatal ischaemic stroke. If no event, censoring occurs at the patient withdrawal of consent, last contact, or death (when applicable)-whichever was later.
Interventions
- DRUG Placebo
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,206 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
What the finished NCT01107886 record still lists
NCT01107886 is an interventional study that assigns participants to a tested intervention. Its 18,206 participants enrollment target places it among the larger protocols in the corpus, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (3428% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01107886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01107886 about?
NCT01107886 is a clinical study titled "Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications". The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
What is the current status of trial NCT01107886?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18,206 participants. The study started on 2010-05. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01107886?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT01107886?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01107886's enrollment target sits among peer trials
18,206 6th of 2000 higher than 1,995 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
- NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia